HSP90AA1 and pemphigus: In addition, no consistent trend towards an increase or reduction of circulating Hsp90 was found in these pemphigus patients after a mean follow-up time of 41 weeks of immunosuppressive treatment (P = 0.36, Figure 2f), during which a decrease in circulating anti-desmoglein 3 (from 1159.1±1835.2 U/ml to mean 27.7±28.4 U/ml; P<0.05, Figure 2g) and 1 autoantibodies (from mean 148.4±312.9 U/ml to mean 1.4±2.9 U/ml; P = 0.08, Figure 2h) as well as healing of skin lesions (all 10 patients with active blistering went into complete remission) was observed.